PURPOSE Scoring proliferation through Ki67 immunohistochemistry is an important component in predicting therapy response to chemotherapy in patients with breast cancer. However, recent studies have cast doubt on the reliability of "visual" Ki67 scoring in the multicenter setting, particularly in the lower, yet clinically important, proliferation range. Therefore, an accurate and standardized Ki...

INTRODUCTION Breast cancer (BC) is a major health problem in Egypt and worldwide. Its prognosis depends not only on tumor stage but also on tumor biology. AIM To correlate the expression of Ki67 with the clinical outcomes of early hormone-receptor positive postmenopausal BC patients who are receiving tamoxifen. METHODS This cohort study included 70 patients. They were followed up for a mini...

This study of early CIN biopsies (25 CIN1 and 65 CIN2) with long follow-up was done to validate, in a new group of patients, the value of Ki67 immuno-quantitative features to predict high CIN grade in a follow-up biopsy (often denoted to as "progression"), as described in a previous study. Each biopsy in the present study was classified with the previously described Ki67-model (consisting of th...

UNLABELLED BACKGROUND Ki67 is widely used in order to distinguish the "A" and "B" subtypes of luminal-type breast cancer. This study aimed to validate the prognostic value of adding p53 to Ki67 for characterizing luminal-type breast cancer. METHODS Immunostaining for Ki67, p53, and the molecular markers HER2, CK5/6, CK14, EGFR, FOXA1, GATA3, and P-cadherin was examined hormone receptor (HR...

ناطرس ىضرم يف Ki67 ةغبصل يعانلما روهظلا طنم مييقت :فادهلأا .Ki67 ل ةنكمم ةينهكت وأ ةيؤبنت ةميق يأ صحفو تايدوعسلا يدثلا Ki67 رشؤلم يمك مييقت فدهب تممص ةيداعتسا ةسارد هذه :ةقيرطلا ةيدوعس ةضيرم 115 نم يدثلا ماروأ تانيع يف يرثاكتلا )Ki67 PI( كللما ىفشتسم ،ىجولوثابلا مسقب 2015 سرامو رياني ينب تصخشُ ينب ةقلاعلا تطبرو .ةيدوعسلا ةيبرعلا ةكلملما ،ةرونلما ةنيدلما ،دهف ،ةيعانلما تاغبصلل ةكرتشلماو ةيدرفلا ج...

BACKGROUND The proliferation marker Ki67 has been suggested as a promising cancer biomarker. As Ki67 needs an exact quantification, this marker is a prototype of a new generation of tissue-based biomarkers. In this study, we have systematically evaluated different cut points for Ki67 using three different clinical end points in a large neoadjuvant study cohort. PATIENTS AND METHODS We have ev...

This study aimed to investigate the correlation between the expression of Ki67 and FasL and prognosis of cervical carcinoma and to explore the biological processes and signal pathways related to cervical carcinoma. Cervical carcinoma tissue specimens from 200 patients and normal tissue specimens adjacent to lesions from 30 cases were collected in this study. Ki67 and FasL proteins in these spec...

PURPOSE The value of Ki67 measured on residual disease after neoadjuvant chemotherapy is not sufficiently described. EXPERIMENTAL DESIGN Participants of the GeparTrio study with primary breast cancer randomly received neoadjuvant response-guided [8 cycles TAC (docetaxel/doxorubicin/cyclophosphamide) in responding and TAC-NX (vinorelbine/capecitabine) in nonresponding patients] or conventional...

The proliferation indices (PIs) were determined in 33 meningiomas using two monoclonal antibodies to the Ki-67 antigen (Ki-67 and MIB1). PIs obtained using Ki-67 on frozen material were intermediate between the lowest and highest MIB1 PIs determined in paraffin wax sections. Preoperative embolisation did not influence Ki67 PI, but four of the 15 embolised tumours showed substantially increased ...